TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO),...
* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001...
TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approva...
TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significan...